Experts discuss the emergence of checkpoint inhibition in the first-line treatment of SCCHN as well as its ongoing role in second-line treatment.
This activity is intended for oncologists, surgeons, and pathologists.
The goal of this activity is to discuss the evolving role of immunotherapy in patients with squamous cell carcinoma of the head and neck (SCCHN).
Approximate Time to Complete: 30 minutes
Credit Available: Mar. 26, 2019 - Mar. 26, 2020
Developed through a partnership between SITC and Medscape.
Upon completion of this activity, participants will be able to:
- Have increased knowledge regarding the emerging clinical data on the use of cancer immunotherapies in the management of SCCHN
- Have greater competence related to Selection of regimens for patients with SCCHN